• Policy
• Reimbursement extended for 18 Factor VIII hemophilia drugs
• by Kim, Jung-Ju Jul 24, 2023 05:26am

• Opinion
• [Reporter's view] A groundbreaking policy is needed
• by Lee, Tak-Sun Jul 24, 2023 05:26am

• Policy
• BMS makes 2nd voluntary price cut for Baraclude this year
• by Lee, Tak-Sun Jul 24, 2023 05:26am

• Company
• CDK4/6 anticancer drug is very active in early breast cancer
• by Jung, Sae-Im Jul 24, 2023 05:25am

• Company
• The synergy between strengths & strengths
• by Kim, Jin-Gu Jul 21, 2023 05:41am

• Policy
• Original for Parkinson's dz tx released are withdrawn
• by Lee, Tak-Sun Jul 21, 2023 05:41am

• Company
• Exports of botulinum in the first half rose by 26%
• by Kim, Jin-Gu Jul 21, 2023 05:41am

• Company
• Korean pharmas busy recruiting talent from global pharmas
• by Lee, Seok-Jun Jul 21, 2023 05:41am

• Company
• NHIS starts RSA reevaluations for AD drug Dupixent
• by Eo, Yun-Ho Jul 21, 2023 05:40am

• Policy
• How Scemblix received reimb without negotiations
• by Lee, Tak-Sun Jul 21, 2023 05:40am